Shocking Updates in the Management of Cardiogenic Shock

<p>Andrew J. Jatis, Pharm.D. (<a href='https://twitter.com/jatis_rx'>@jatis_rx</a>), recognizes the clinical heterogeneity of cardiogenic shock and its impact on clinical outcomes, describes current literature assessing vasopressors and inotropes in the management of cardiogenic shock, and determines an optimal pharmacologic regimen for the treatment of cardiogenic shock given individual patient characteristics. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>